– UK, Oxford – Oxford Biomedica PLC (LON: OXB), a quality and innovation-led cell and gene therapy CDMO, today announced the appointment of Colin Bond to its Board as a Non-Executive Director effective 1 January 2025.
Colin Bond will also join the Audit Committee.
“Colin is a highly strategic operator with extensive international CDMO and healthcare sector expertise plus first-rate technical accounting credentials. He is well regarded by the investment community and has overseen organisations that have undergone significant growth and transformation. On behalf of the Board, I am delighted to welcome Colin to OXB and thoroughly look forward to working with him,” said Board Chair, Dr. Roch Doliveux.
Additionally, the company announced that Leone Patterson will step down from the Board on 31 December 2024.
About Colin Bond
Colin Bond has a wealth of international experience in the CDMO and biopharma industries and was most recently CFO of Sandoz listed on the SIX Swiss Exchange, where he played a key role in the company’s successful spin-off from Novartis. Before Sandoz, he was CFO of Vifor Pharma and Evotec. He also served as Chair of the Audit Committee for Siegfried AG, a leading CDMO quoted on the SIX Swiss Exchange, for ten years until May 2023. He is currently Chair of the Audit Committee of BioPharma Credit PLC on the London Stock Exchange and a member of the Supervisory Board of Formycon AG.
During his early career, Colin Bond worked as a pharmacist, auditor, and management consultant for Procter & Gamble, Arthur Andersen, and PwC.
Colin Bond is a Fellow of the Institute of Chartered Accountants in England and Wales and a Member of the Royal Pharmaceutical Society of Great Britain. He holds a BSc in Pharmacy from Aston University and an MBA from London Business School.
Colin Bond said: “OXB’s position as a leader in cell and gene therapy manufacturing, combined with its innovative approach and strong client partnerships, presents a compelling opportunity that I have recently watched with interest. I am excited to join the Board at this important time and look forward to working with the team to support OXB’s continued growth and success in enabling the delivery of life-changing therapies to patients worldwide.”
About OXB
OXB is a quality and innovation-led contract development and manufacturing organization in cell and gene therapy with a mission to enable its clients to deliver life-changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, OXB has more than 25 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus, adenovirus, and other viral vector types. OXB’s world-class capabilities span from early-stage development to commercialization. These capabilities are supported by robust quality-assurance systems, analytical methods, and depth of regulatory expertise.
OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the Tetravecta™ system), a dual plasmid system for AAV production, suspension and perfusion process using process enhancers, and stable producer and packaging cell lines.
For more: https://oxb.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.